From a series of previously synthesized phenanthroline-based ligands possessing anti-tumor properties, 2,9-disecbutyl-1,10-phenanthroline(sec-butylphen) was utilized as a drug treatment on glioblastoma tumor cell lines. Glioblastoma multiforme is an extremely aggressive and invasive form of central nervous system (CNS) tumor. A common chemotherapeutic drug used to treat advanced glioblastomas is Temozolomide (TMZ). In an effort to assess the anti-tumor capabilities of sec-butylphen, in-vitro and in-vivo studies were considered using proliferative GL-26 glioma cells. GL-26 glioma cells were cultured in-�vitro and incubated with concentrations of sec-butylphen or Temozolomide. The drug was then removed and cell growth compared to non-treated cells was assessed using the Sulforhodamine B (SRB) colorimetric viability assay. To determine the toxicity window of the drug between tumor cells and normal cells, human foreskin fibroblasts (HFF) cells treated with sec-butylphen and toxicity was assessed using SRB. Our data demonstrate improved and strong toxicity against GL-26 cells compared to TMZ in-vitro. Furthermore, in-vivo studies were done using mice in which a GL-26 cell line was established by an intracranial injection 1mm anterior and 2 mm lateral to the junction of the coronal and sagittal sutures (bregma) at a depth of 2mm using a stereotactic mouse frame. sec-butylphen injections were given intravenously through the retro-orbital route on day 1, 7 and 13 post tumor implantation.. In-vivo experiments demonstrate a significant reduction in tumor growth with administration of sec-butylphen. These experiments suggest sec-butylphen is effective in slowing CNS glioblastoma progression and should be considered as a potential compound for future anticancer drug development.

Antitumor efficacy of a potential glioblastoma chemotherapeutic

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.